NEW YORK (GenomeWeb News) – Cantor Fitzgerald on Monday initiated coverage of molecular diagnostics firm Trovagene with a Buy rating and a $10 price target on the company's stock.

In a research report, analyst Sung Ji Nam said that the San Diego-based firm's technology platform is capable of analyzing systemic cell-free DNA and RNA isolated from urine and could be used as a non-invasive diagnostic with applications across multiple disease areas and health conditions, including cancer, infectious diseases, transplant medicine, and prenatal diagnostics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.